Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · CellCept
CellCept 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-085176 · Präparat HOS-083095
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3104–3853 im Abschnitt
Wechselwirkungen · CellCept
CellCept 500 mg powder for concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 29
HOS-085264 · Präparat HOS-083095
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 2395–3144 im Abschnitt
Wechselwirkungen · CellCept
CellCept 1 g/5 ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 50
HOS-085327 · Präparat HOS-083095
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3109–3858 im Abschnitt
Wechselwirkungen · CellCept
CellCept 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 73
HOS-085398 · Präparat HOS-083095
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-07T14:22:00Z · SHA-256 8464b0a5294445d85b3f9b902633989ca6f57af3990241a80eda4979936ba419 · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3108–3857 im Abschnitt
Wechselwirkungen · Tamiflu
Tamiflu 30 mg hard capsules Tamiflu 45 mg hard capsules Tamiflu 75 mg hard capsules · Abschnitt 4.5 · PDF-Seite 7
HOS-110026 · Präparat HOS-093293
Amoxicillin
Oseltamivir has no kinetic interaction with amoxicillin, which is eliminated via the same pathway,
suggesting that oseltamivir interaction with this pathway is weak.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T13:27:00Z · SHA-256 49e3275593869eab140681f5cba3d7da7ff895500b27bac431ac12de5f5745b2 · Passage 6aef3e515ab9ff3e07b0b807d9330a31d8c91223ddde16970f48b577665d3c3d · Zeichen 566–743 im Abschnitt
Wechselwirkungen · Tamiflu
Tamiflu 6 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 35
HOS-110066 · Präparat HOS-093293
Amoxicillin
Oseltamivir has no kinetic interaction with amoxicillin, which is eliminated via the same pathway,
suggesting that oseltamivir interaction with this pathway is weak.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-15T13:27:00Z · SHA-256 49e3275593869eab140681f5cba3d7da7ff895500b27bac431ac12de5f5745b2 · Passage 6aef3e515ab9ff3e07b0b807d9330a31d8c91223ddde16970f48b577665d3c3d · Zeichen 624–801 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-209315 · Präparat HOS-154301
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3125–3874 im Abschnitt
Wechselwirkungen · Mycophenolate mofetil Teva
Mycophenolate mofetil Teva 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-209394 · Präparat HOS-154301
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:35:00Z · SHA-256 61cafb6c3b2c402ab0fadec97be0fb0c1f5e7800a3e7542ee2a6307b124af700 · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3124–3873 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 8
HOS-209464 · Präparat HOS-154315
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3125–3874 im Abschnitt
Wechselwirkungen · Myfenax
Myfenax 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-209533 · Präparat HOS-154315
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil
should not normally be necessary in the absence of clinical evidence of graft dysfunction. However,
close clinical monitoring should be performed during the combination and shortly after antibiotic
treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T12:04:00Z · SHA-256 1eac250c72b4f0a4fe3012df5ca65f8295e08fe953b2900f2e41cf74ecbe8efc · Passage 4bd1292f9e3f6d1853c880dd51e7a3e55450c016d6db3b80ef4f0f7a6ca28174 · Zeichen 3125–3874 im Abschnitt
Wechselwirkungen · Myclausen
Myclausen 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-212906 · Präparat HOS-155006
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of Myclausen should not
normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical
monitoring should be performed during the combination and shortly after antibiotic treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T14:45:00Z · SHA-256 5212e91cac7f54413fc4524ec82e254c35610b87ec825a71d5d295c67a8c8df9 · Passage ac3464cab49c7a55db61ca5503d08b75e40abbfb36bf9dfd2ba5e4e59e8680f1 · Zeichen 3087–3824 im Abschnitt
Wechselwirkungen · Myclausen
Myclausen 250 mg hard capsules · Abschnitt 4.5 · PDF-Seite 25
HOS-212966 · Präparat HOS-155006
Ciprofloxacin or amoxicillin plus clavulanic acid
Reductions in pre-dose (trough) MPA concentrations of about 50% have been reported in renal
transplant recipients in the days immediately following commencement of oral ciprofloxacin or
amoxicillin plus clavulanic acid. This effect tended to diminish with continued antibiotic use and to
cease within a few days of antibiotic discontinuation. The change in pre-dose level may not accurately
represent changes in overall MPA exposure. Therefore, a change in the dose of Myclausen should not
normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical
monitoring should be performed during the combination and shortly after antibiotic treatment.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) ciprofloxacin (HOS-085177) clavulanic acid (HOS-085179)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-10T14:45:00Z · SHA-256 5212e91cac7f54413fc4524ec82e254c35610b87ec825a71d5d295c67a8c8df9 · Passage ac3464cab49c7a55db61ca5503d08b75e40abbfb36bf9dfd2ba5e4e59e8680f1 · Zeichen 3087–3824 im Abschnitt
Wechselwirkungen · Nexium Control
Nexium Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-127736 · Präparat HOS-096457
Investigated medicinal products with no clinically relevant interaction
Amoxicillin and quinidine
Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of
amoxicillin and quinidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:26:00Z · SHA-256 d4554b4b11397de3effc8bd7e120a7d0370b488e26268f079cad37ef37aaaf22 · Passage eecaca9c78254db1233aba80a1a557884c2c1bc824142a1ef282d1b358a29734 · Zeichen 7375–7593 im Abschnitt
Wechselwirkungen · Nexium Control
Nexium Control 20 mg gastro-resistant hard capsules · Abschnitt 4.5 · PDF-Seite 19
HOS-127774 · Präparat HOS-096457
Investigated medicinal products with no clinically relevant interaction
Amoxicillin and quinidine
Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of
amoxicillin and quinidine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): amoxicillin (HOS-085178) quinidine (HOS-085593)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-13T14:26:00Z · SHA-256 d4554b4b11397de3effc8bd7e120a7d0370b488e26268f079cad37ef37aaaf22 · Passage eecaca9c78254db1233aba80a1a557884c2c1bc824142a1ef282d1b358a29734 · Zeichen 7386–7604 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.